drugset / Trial / NCT00823212

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions

NCT00823212

Phase 3 Completed 1530 enrolled Boston Scientific Corporation
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions. This clinical trial compares outcomes in patients treated with PROMUS Element to those in patients treated with a different everolimus-eluting coronary stent. The lesions are of average length in average-sized vessels ("workhorse"). A companion sub-trial evaluates outcomes in smaller vessels (SV) and another sub-trial evaluates outcomes in longer lesions (LL).

Timeline

Start
2009-01
Primary completion
2010-09
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Background Aspirin Small molecule 75 mg
Background Aspirin Small molecule 162 mg
Background Aspirin Small molecule 325 mg
Background Clopidogrel Small molecule 75 mg
Background Prasugrel Small molecule
Background ticlopidine Small molecule 250 mg